Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2

Status

Completed 4Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 18INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 7Gynecologic 6Other hematologic neoplasm 5Genitourinary 5Breast 5Lymphoid 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 2Small Cell Lung Carcinoma 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Inoperable Stage III Non-small Cell Lung Cancer 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Saline Solution × Thoracic × Clear all
NCT07246863 2026-04-21

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

CatalYm GmbH

Phase 2 Recruiting
131 enrolled
Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT03515837 2024-11-22

MK-3475-789

Merck Sharp & Dohme LLC

Phase 3 Completed
492 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
616 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
40 enrolled 20 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03066778 2022-10-03

KEYNOTE-604

Merck Sharp & Dohme LLC

Phase 3 Completed
453 enrolled 23 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT00850577 2015-10-12

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Bristol-Myers Squibb

Phase 2 Terminated
255 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01579188 2012-04-19

LucaVax

Kael-GemVax Co., Ltd.

Phase 3 Unknown
600 enrolled
Thoracic

Inoperable Stage III Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡